GlassScriptPhysician profile
Leslie A Willingham
NPI 1174787790
$5,809.36
in general payments reported to CMS, 2019-2025
50 companies · $737 in 2025
The $737 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $75.41 · 2021: $651 · 2022: $670 · 2023: $1,385 · 2024: $1,073 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.89 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Novo Nordisk INC | $618.34 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $458.01 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $385.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $371.00 | 2019-2025 | |
| Lilly USA, LLC | $312.35 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $309.65 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $287.49 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $256.74 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.10 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $196.85 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $132.27 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.84 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $96.27 | 2019-2025 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $80.75 | 2021-2025 | Epclusa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Willingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.